Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 986.5 DKK -1.32% Market Closed
Market Cap: 127.4B DKK
Section:
 

Relative Value

The Relative Value of one GMAB stock under the Base Case scenario is 521.19 DKK. Compared to the current market price of 1 986.5 DKK, Genmab A/S is Overvalued by 74%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GMAB Relative Value
Base Case
521.19 DKK
Overvaluation 74%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

34.1
P/S
P/S
Price to Sales
34.1
vs History
79
vs Industry
66
Median 3Y
48.9
Median 5Y
79.7
Industry
7.9
Forward
32.8
More Details
82.5
P/E
P/E
Price to Earnings
82.5
vs History
84
vs Industry
10
Median 3Y
159.7
Median 5Y
220.5
Industry
23.7
Forward
105.8
More Details
95.9
P/OCF
P/OCF
Price to OCF
95.9
vs History
82
vs Industry
13
Median 3Y
123
Median 5Y
164.8
Industry
22
More Details
103
P/FCFE
P/FCFE
Price to FCFE
103
vs History
82
vs Industry
11
Median 3Y
131.7
Median 5Y
175.8
Industry
23.8
More Details
21.3
P/B
P/B
Price to Book Value
21.3
vs History
77
vs Industry
38
Median 3Y
26.8
Median 5Y
42.3
Industry
3.3
More Details
33.2
EV/S
EV/S
Enterprise Value to Sales
33.2
vs History
79
vs Industry
61
Median 3Y
47.3
Median 5Y
78
Industry
8.3
Forward
31.9
More Details
35.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
35.2
vs History
41
vs Industry
64
Median 3Y
43.9
Median 5Y
32.5
Industry
10.1
More Details
85.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
85.8
vs History
82
vs Industry
12
Median 3Y
146.1
Median 5Y
157.6
Industry
6.4
Forward
84.2
More Details
90.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
90.2
vs History
82
vs Industry
10
Median 3Y
147.9
Median 5Y
164.2
Industry
7
Forward
91.1
More Details
93.4
EV/OCF
EV/OCF
Enterprise Value to OCF
93.4
vs History
82
vs Industry
14
Median 3Y
119.5
Median 5Y
161.1
Industry
8.3
More Details
98.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
98.9
vs History
82
vs Industry
10
Median 3Y
125.6
Median 5Y
169.2
Industry
6.5
More Details
33
EV/IC
EV/IC
Enterprise Value to IC
33
vs History
74
vs Industry
42
Median 3Y
114
Median 5Y
163.1
Industry
5.7
More Details

Multiples Across Competitors

GMAB Competitors Multiples
Genmab A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Genmab A/S
CSE:GMAB
122.3B DKK 34.1 82.5 85.8 90.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 770 229.5 -160 504.9 -194 904.1 -192 680.1
US
Abbvie Inc
NYSE:ABBV
395.3B USD 6.6 168.4 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD 5.1 18.2 12.2 12.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.1 -532.3 -579.6 -564.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
84.7B AUD 3.6 18.7 12.6 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 183.4 155.3 188.4
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 34 58.6 60.2
P/S Multiple
Revenue Growth P/S to Growth
DK
Genmab A/S
CSE:GMAB
Average P/S: 3 070 219.6
34.1
16%
2.1
FR
Pharnext SCA
OTC:PNEXF
33 770 229.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 086.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.3
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
DK
Genmab A/S
CSE:GMAB
Average P/E: 175.4
82.5
9%
9.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 504.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 183.4
N/A N/A
NL
argenx SE
XBRU:ARGX
34
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBITDA: 44.3
85.8
22%
3.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 904.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
7%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.6
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBIT: 50.1
90.2
20%
4.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 680.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.4
N/A N/A
NL
argenx SE
XBRU:ARGX
60.2
N/A N/A

See Also

Summary
GMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
GMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GMAB stock valuation using valuation multiples.
Wall Street Estimates
GMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.